{"issuance_frequency":"","notes_translated":{"fr":"Le document que voici vise à suggérer des éléments qu'il faut prendre en considération au moment de concevoir des essais cliniques visant l'éradication de Helicobacter pylori dans les maladies gastro-intestinales et à énumérer des éléments qu'il faudrait examiner quand un de ces régimes fait part d'un dossier de médicament. Il donne plus de précisions sur la conception d'essais cliniques menés auprès d'une population comprenant des sujets souffrant d'un ulcère duodénal actif. Dans le cas des autres pathologies gastro-intestinales associées à H. pylori, le guide décrit les éléments devant être pris en considération dans le plan d'étude. ","en":"The purpose of this document is to suggest elements for consideration when designing clinical trials dealing with eradication of H. pylori in GI diseases and to outline elements to be reviewed in the submissions. It expands on the design of clinical trials when patients with active duodenal ulcers are included as subjects in clinical trials. For other Hp associated GI diseases, the guide provides elements to be considered in the study design. "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"04238ae0-194d-4154-b009-18d7a46ee94f","metadata_created":"2021-07-07T16:41:48.029971","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T16:41:48.029978","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Orientation","développement de schémas thérapeutiques","éradication","éradication de Helicobacter pylori","maladies gastro-intestinales"],"en":["Guidance","developing therapeutic regimens","eradication","eradication of helicobacter pylori","GI diseases"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Guide pour le développement des régimes thérapeutiques visant à éradiquer Helicobacter pylori dans les maladies gastro-intestinales","en":"Guidance when Developing Therapeutic Regimens for the Eradication of Helicobacter pylori in GI diseases"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"04238ae0-194d-4154-b009-18d7a46ee94f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5e4b3809-af0b-4aab-b0e6-b678eaf65d5c","related_relationship":"","name_translated":{"fr":"Guide pour le développement des régimes thérapeutiques visant à éradiquer Helicobacter pylori dans les maladies gastro-intestinales","en":"Guidance when Developing Therapeutic Regimens for the Eradication of Helicobacter pylori in GI diseases"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance when Developing Therapeutic Regimens for the Eradication of Helicobacter pylori in GI diseases","language":["en"],"created":"2021-07-07T16:41:48.126784","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/helicobacter-pylori/guidance-when-developing-therapeutic-regimens-eradication-helicobacter-pylori-diseases.html","last_modified":null,"position":0,"revision_id":"db2eec63-4e5e-4015-8280-7058cd8d016c","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"04238ae0-194d-4154-b009-18d7a46ee94f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"26852ada-8ac0-4710-9200-3748e1a94eaf","related_relationship":"","name_translated":{"fr":"Guide pour le développement des régimes thérapeutiques visant à éradiquer Helicobacter pylori dans les maladies gastro-intestinales","en":"Guidance when Developing Therapeutic Regimens for the Eradication of Helicobacter pylori in GI diseases"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance when Developing Therapeutic Regimens for the Eradication of Helicobacter pylori in GI diseases","language":["fr"],"created":"2021-07-07T16:41:48.126792","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/helicobacter-pylori/guide-developpement-regimes-therapeutiques-visant-eradiquer-helicobacter-pylori-maladies-gastro-intestinales.html","last_modified":null,"position":1,"revision_id":"db2eec63-4e5e-4015-8280-7058cd8d016c","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2010-02-12 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"04238ae0-194d-4154-b009-18d7a46ee94f","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The purpose of this document is to suggest elements for consideration when designing clinical trials dealing with eradication of H. pylori in GI diseases and to outline elements to be reviewed in the submissions. It expands on the design of clinical trials when patients with active duodenal ulcers are included as subjects in clinical trials. For other Hp associated GI diseases, the guide provides elements to be considered in the study design. ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance when Developing Therapeutic Regimens for the Eradication of Helicobacter pylori in GI diseases","revision_id":"db2eec63-4e5e-4015-8280-7058cd8d016c"}